A Case of Type 1 Diabetes Mellitus in a Patient With Type 2 Diabetes Mellitus during Treatment With Pembrolizumab
-
- Shimizu Takayuki
- Department of Internal Medicine, Ozu Memorial Hospital
-
- Furukawa Shinya
- Health Services Center, Ehime University
-
- Fujioka Yusuke
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
-
- Kanamoto Mayumi
- Department of Diabetes, Uwajima City Hospital
-
- Tamai Jyunichirou
- Diabetes and Thyroid Center, Saiseikai Matsuyama Hospital
-
- Umeoka Fumi
- Diabetes and Thyroid Center, Saiseikai Matsuyama Hospital
-
- Miyaoka Hiroaki
- Diabetes and Thyroid Center, Saiseikai Matsuyama Hospital
Bibliographic Information
- Other Title
-
- 2型糖尿病治療経過中にペムブロリズマブ投与後に発症した1型糖尿病の1例
Search this article
Abstract
<p>A 53-year-old man visited our hospital because of severe appetite loss, thirst, and nausea. He had been receiving treatment for type 2 diabetes mellitus for the past nine years and had also been receiving pembrolizumab therapy as second-line treatment for ureter cancer for the past three months. Severe hyperglycemia, insulin secretion deficiency (fasting plasma C-peptide, 0.3 ng/mL), and ketosis after pembrolizumab administration led to the diagnosis of pembrolizumab-induced type 1 diabetes mellitus. Even two years after the onset of type 1 diabetes mellitus, his insulin secretion remained decreased. Several cases of programmed death receptor-1 (PD-1) antibody-induced type 1 diabetes mellitus in patients with type 2 diabetes mellitus have been reported. Previous case reports revealed that the HbA1c value at the diagnosis in PD-1 antibody-induced type 1 diabetes mellitus that developed from type 2 diabetes mellitus was higher than X, and all reported cases were in men. Immune checkpoint inhibitors, including PD-1 antibody, are widely used for advanced malignancy treatment in patients with type 2 diabetes mellitus. Clinicians should thus carefully monitor patients for ketosis or ketoacidosis-related symptoms, glycemic control, and endogenous insulin secretion when administering PD-1 antibody therapy, even in those who already have type 2 diabetes mellitus.</p>
Journal
-
- Journal of the Japan Diabetes Society
-
Journal of the Japan Diabetes Society 65 (12), 672-679, 2022-12-30
THE JAPAN DIABETES SOCIETY
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390294595557174400
-
- ISSN
- 1881588X
- 0021437X
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed